Skip to main content

Jolla Value Stock - Dividend - Research Selection

La Jolla Pharmaceutical

ISIN: US5034596040, WKN: A1XB6B

Market price date: 05.08.2022
Market price: 6,20 USD

La Jolla Pharmaceutical Fundamental data and company key figures of the share

Annual reports in USD
Key figures 12-03-2022
Cash flow
Net operating cash flow 28.244.000
Capital Expenditures -9.000
Free cash flow 28.235.000
Balance sheet
Total Equity -66.738.000
Liabilities & Shareholders equity 101.230.000
Income statement
Net income 19.660.000
Eps (diluted) 0,580
Diluted shares outstanding 27.497.000
Net sales/revenue 75.720.000

Fundamental ratios calculated on: 05-08-2022

Key figures 05-08-2022
Cash flow
P/C 6,04
P/FC 6,04
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization170.481.408,00 USD
CountryUnited States
Raw Data SourceUS GAAP in Millionen USD
Stock Split2014-01-14,1.000000/50.000000; 2012-02-17,1.000000/100.000000; 2011-04-15,1.000000/100.000000; 2005-12-22,1.000000/5.000000

Description of the company

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Stocks making the biggest moves midday: Bausch Health, Meta, Comcast, Qualcomm and more

These are the stocks posting the largest moves in midday trading.

Comcast earnings beat Wall Street's estimates, reports flat broadband subscribers

CNBC's 'Squawk Box' team breaks down the latest earnings results from Comcast, which beat analysts' expectations on the top and bottom lines.

Stocks making the biggest moves in the premarket: Stanley Black & Decker, Southwest Airlines, Harley-Davidson and more

The stocks making the biggest moves in premarket trading include Stanley Black & Decker, Southwest Airlines, Harley-Davidson, and more.

Comcast fails to add broadband subscribers for first time ever as economy slows

Comcast beat revenue and profit estimates but failed to deliver broadband subscriber growth. Peacock subscriber numbers were also flat.

Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

WWE at crossroads as Vince McMahon's retirement and scandals heighten sale speculation

WWE can either move forward with sale discussions or take the business in new creative directions as Vince McMahon retires from his executive roles.

Sesame Solar is selling mobile disaster relief units powered entirely by clean energy

Sesame sells the systems for anywhere from $100,000 to $300,000, or more for larger installations like a full medical clinic.

Markets face what could be the most important week of summer with Fed, earnings and economic data

There's a head spinning amount of news for markets to navigate in the week ahead, the biggest of which will be the Federal Reserve's mid-week meeting.

Hollywood finally comes calling for horror writer Paul Tremblay

"Knock at the Cabin," a new film by director M. Night Shyamalan, is the first adaptation of one of Paul Tremblay's horror novels.

At amusement parks like Six Flags and Disney, safety is a multimillion-dollar business

Ride-related injuries dropped by more than 60% between 2004 and 2019, according to the International Association of Amusement Parks and Attractions.